Home / Intelligence / White Papers / Empowering Cancer Immunotherapy: Unleashing the Potential of NK Cell Therapies in Oncology
Cell therapies are becoming increasingly incorporated as late-line standards of care across relapsed/refractory oncology indications, with an expanding ability to improve outcomes for a diverse set of tumors and patient subgroups. As the next frontier of personalized and precision medicine continues to grow, Natural Killer (NK) cell therapies offer the potential to penetrate untapped needs across a variety of cancers. However, enthusiasm surrounding the opportunity offered by NK-based technologies has fluctuated over recent years. Several large pharma leaders have made significant early investments in the NK space, signaling potential for sizeable clinical and commercial opportunity. At the same time, emerging data from small biotechs at the forefront of NK innovation warrant a more critical perspective on the new technology.
While unlikely to evolve into frontline standard of care or displace CAR-Ts as they themselves move into earlier lines, NK cell therapies harness unique clinical value not offered by existing therapeutics to fulfill key unmet needs in cancer treatment today. Firstly, NK cell therapies have shown minimal risk of cytokine release syndrome (CRS), neurotoxicity and graft versus host disease (GvHD), which are all common severe adverse events associated with CAR-T cell therapies. Secondly, most NK cell therapies currently in development are allogeneic (“off-the-shelf”), which reduces long manufacturing time and production costs constraining broad uptake of current CAR-Ts. Lastly, while additional evidence is required, NK cell therapies and NK adjacent technologies may extend value beyond hematologic malignancies into solid tumors, assuming that adequate tumor infiltration and persistence in the solid tumor microenvironment (TME) can be demonstrated. NK cell therapy thus has the potential to transform the innate immune cell therapy landscape and find a niche in oncology that maximizes value to patients. Biopharma leaders invested in cell therapy and/or oncology must continue to monitor the NK cell therapy space as near-term catalysts, if positive, are likely to attract heightened attention and trigger significant investments.
Complete the form below to access the full white paper
Annual State of Global Market Access
In 2023, the life sciences industry saw key therapeutic advances in sickle cell disease, obesity/weight management, and Duchenne muscular dystrophy, among others, and the continued approvals of therapies with cutting edge mechanisms, including the first CRISPR therapy. While 2022 was characterized by accelerated development processes and the rapid evolution of therapeutic standards, 2023 featured increased […]
Cell and Gene Therapies: Six Global Trends We Are Watching in 2024
2023 was a busy year for cell and gene therapies (C>). There were regulatory approvals in the U.S. and EU, including both in rare pediatric conditions with no current effective options (e.g., Duchenne muscular dystrophy (DMD)), as well as in indications where competition is better established (e.g., hemophilia A and B). Towards the end of […]
Priced Out: Generic Therapy Price Competition and Drug Shortages
Introduction In the summer of 2023, many oncologists and cancer patients faced an impossible choice. Amidst many challenging treatment decisions, they had to determine how to proceed without two mainstays among oncology therapeutics: cisplatin and carboplatin. While it can sometimes be expected that there may be delays for the newest and most innovative treatments to […]